PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations.
Wei‐Pang Chung, Wei-Lun Huang, Chun‐Hui Lee, Hui‐Ping Hsu, Wanling Huang, You‐Yu Liu, Wu‐Chou Su
Abstract
effects of alpelisib plus trastuzumab were tested and confirmed in a mouse model, showing the combination strategy offered the best opportunity to achieve tumor volume reduction. With known safety profiles, this cytotoxic chemotherapy-free regimen warrants further attention as a biomarker-driven strategy for treating HER2-positive breast cancer.
Topics & Concepts
PTENTrastuzumabPI3K/AKT/mTOR pathwayCancer researchBreast cancerEstrogen receptorCancerMedicineCarcinogenesisInternal medicineSignal transductionBiologyCell biologyHER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies